PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables. Began shipping GEM-X Flex, sett ...

财务信息 - 10x Genomics公司发布了2024年第三季度的初步业绩[3] - 公司未提供具体的财务数据和业绩指引[3] 公司信息 - 公司未透露任何关于用户数据、新产品和新技术研发、市场扩张和并购、其他新策略等方面的信息[2,3,4] - 公司未在电话会议上分享任何深度研究报告或洞察[2,3,4] - 公司未提供任何行业趋势分析或对未来的展望[3]

文章核心观点 - 10x Genomics公司即将于2024年10月29日公布第三季度财报 [1] - 公司的主要业务包括Visium和Zenium两大空间生物学平台,以及Chromium单细胞生物学平台 [2] - 第三季度公司的耗材销售有望保持强劲增长,但仪器销售可能受到客户预算压力的影响而下滑 [3][4] - 公司此前已下调了全年收入指引,预计第三季度收入将同比下降1% [5][6] 根据相关目录分别进行总结 收入情况 - 第三季度收入预计约为1.517亿美元,同比下降1% [6] - 其中仪器销售下降46%,耗材销售增长10%,服务收入增长48% [6] - 公司下调了全年收入指引,从6.7-6.9亿美元降至6.4-6.6亿美元 [5] 盈利情况 - 第三季度每股亏损预计为0.34美元,同比改善33.3% [7] - 公司有望实现季度业绩超预期,因其目前具备正面的盈利预测修正值(ESP)和1级买入评级 [8] 同行业公司表现 - Masimo公司第三季度业绩有望超预期,过去4个季度平均超预24.63% [9] - ACADIA Pharmaceuticals第三季度业绩有望大幅改善,同比增长127.5% [10] - Privia Health Group第三季度业绩有望同比增长20%,但过去4个季度均低于预期 [11][12]

文章核心观点 - 10x Genomics公司最近被评为Zacks Rank 1(强烈买入),这表明其盈利前景有所改善,这是影响股价的最强大力量之一[1][2][3] - 公司未来盈利能力的变化,反映在盈利预测的修订上,与股价的近期走势有着密切关联[3] - 10x Genomics公司的盈利预测上调,意味着其基本面有所改善,投资者对此的认可将推动股价上涨[3] 公司研究 - 10x Genomics公司预计2024财年每股收益为-1.35美元,同比增长18.7%[5] - 过去3个月内,分析师对10x Genomics公司的盈利预测不断上调,上调幅度达12%[5] - 10x Genomics公司被评为Zacks Rank 1,位于Zacks覆盖股票的前5%,表明其盈利预测修订优势突出,未来股价有望上涨[6]

文章核心观点 - 10x Genomics预计在2024年第三季度的财报中将实现同比收益增长,但收入将同比下降 [1] - 10x Genomics的实际业绩如何与预期相比将是影响其近期股价的关键因素 [1] - 如果关键财务数据超出预期,股价可能上涨;反之则可能下跌 [1] 根据相关目录分别进行总结 盈利预测 - 10x Genomics预计将在下个季度报告中录得每股亏损0.34美元,同比减少33.3% [2] - 预计收入将为1.5162亿美元,同比下降1.3% [2] 盈利预测修正趋势 - 过去30天内,分析师将该季度的盈利预测下调了15.61% [3] - 这反映了分析师对公司前景的集体重新评估 [3] 业绩预告 - 分析师在财报发布前对预测的修订可以反映该期业务状况 [4] - Zacks Earnings ESP(预期惊喜预测)模型可以预测实际盈利是否会偏离共识预期 [4] - 正的Earnings ESP预示着可能会有正面业绩惊喜 [5] 10x Genomics的情况 - 10x Genomics的最新预测高于共识预期,Earnings ESP为+8.46% [6] - 加上公司目前的Zacks评级为2(买入),表明其很可能会超越共识盈利预期 [6] 历史业绩表现 - 在上一个季度,10x Genomics实际亏损0.32美元,好于预期0.47美元的亏损,实现了31.91%的正面惊喜 [7] - 但过去4个季度中,公司只有1次超越了共识盈利预期 [7]

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications. These launches are part of the company's str ...

文章核心观点 - 10x Genomics公司股价从2021年6月的209美元下跌至20美元,遭受了持续的抛售压力 [1] - 10x Genomics公司报告了一些适度的增长 [1] - 作者是Compounding Healthcare投资组合的负责人,提供了包括模型投资组合、每周通讯、每日观察列表和对话交流等服务 [1] - 作者是一名专注于生物医药行业的全职投资者,对创新疗法和潜在收购机会感兴趣 [1] 公司信息 - 10x Genomics是一家NASDAQ上市公司,股票代码为TXG [1] - 10x Genomics公司专注于生物技术和基因组学领域 [1] 行业信息 - 生物医药行业是作者的主要投资领域,他对创新疗法和潜在收购机会感兴趣 [1]

● ● . Torex Gold Reports Q3 2024 Production Results Solidly on track to deliver full-year production guidance following strong third quarter results October 08, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q3 2024 gold production of 119,412 ounces ("oz") and gold sold of 122,130 oz. With year-to-date gold production of 348,728 oz, the Company is on track to achieve annual go ...

● . ● Torex Gold Welcomes the Addition of a New Director Caroline Donally brings extensive mining sector experience in commerce and financial markets September 23, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to announce the addition of Caroline Donally CA(SA) to its Board of Directors ("the Board") effective October 1, 2024. Rick Howes, Chair of the Board, stated: "Ca ...

In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Ce ...